Clinical trials: Gastroenteropancreatic Neuroendocrine Tumor
Neuroendocrine Tumor G1 (NET G1)/Carcinoid, Neuroendocrine Tumor Grade 2
Comparison of Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases
An international multi-centre, open, randomised, parallel-group phase II study comparing adjuvant treatment with 177Lu-DOTATATE to best supportive care in patients after complete surgical removal of neuroendocrine liver…
- Conditions
- Neuroendocrine Tumor G1 (NET G1)/Carcinoid, Neuroendocrine Tumor Grade 2, Neuroendocrine Tumors, Liver Metastases
- Trial name
- NELMAS (NCT05987176)
- Testing
- Lutathera
- Where
- United Kingdom
- Volunteers
- 1 people
- Sponsor
- Imperial College London
Gastric Neuroendocrine Carcinoma, Intestinal Neuroendocrine Carcinoma
Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas
This randomized phase II trial studies how well temozolomide and capecitabine work compared to standard treatment with cisplatin or carboplatin and etoposide in treating patients with neuroendocrine carcinoma of the…
- Conditions
- Gastric Neuroendocrine Carcinoma, Intestinal Neuroendocrine Carcinoma, Pancreatic Neuroendocrine Carcinoma
- Trial name
- NCT02595424
- Testing
- Capecitabine, Carboplatin, Cisplatin
- Where
- 673 sites in United States
- Volunteers
- 67 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Foregut Neuroendocrine Tumor, Hindgut Neuroendocrine Tumor
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
This randomized phase II trial studies how well pazopanib hydrochloride works in treating patients with carcinoid tumors that are growing, spreading, or getting worse.
- Conditions
- Foregut Neuroendocrine Tumor, Hindgut Neuroendocrine Tumor, Metastatic Digestive System Neuroendocrine Tumor G1, Metastatic Neuroendocrine Tumor
- Trial name
- NCT01841736
- Testing
- Biospecimen Collection, Computed Tomography, Echocardiography Test
- Where
- 423 sites in United States, Canada
- Volunteers
- 171 people
- Sponsor
- National Cancer Institute (NCI)
Gastro-enteropancreatic Neuroendocrine Tumor, Health Care Costs
The Lyon Real World Evidence in Metastatic NeuroEndocrine Tumours
Neuroendocrine tumours (NETs) are rare and include a heterogeneous group of neoplasms derived from the endocrine system found in the gastrointestinal tract, pancreas and lung.
- Conditions
- Gastro-enteropancreatic Neuroendocrine Tumor, Health Care Costs, Metastatic Cancer
- Trial name
- LyREMeNet (NCT03863106)
- Testing
- Metastatic gastroenteropancreatic and lung neuroendocrine tumors
- Where
- France
- Volunteers
- 880 people
- Sponsor
- Hospices Civils de Lyon
Carcinoid Syndrome, Carcinoid Tumor
An Investigational Scan (Dual Energy CT) in Detecting Gastrointestinal Carcinoid Tumors
This trial studies the use of a special type of computed (CT) scan called dual energy CT in detecting gastrointestinal carcinoid tumors.
- Conditions
- Carcinoid Syndrome, Carcinoid Tumor, Digestive System Neuroendocrine Tumor G1, Metastatic Carcinoid Tumor
- Trial name
- NCT04993261
- Testing
- Dual-Energy Computed Tomography
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- M.D. Anderson Cancer Center
Large Cell Neuroendocrine Carcinoma, Large Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC)
Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of [212Pb]Pb-MP0712, in patients aged ≥18 years with Small Cell Lung Cancer and other locally advanced or metastatic DLL3…
- Conditions
- Large Cell Neuroendocrine Carcinoma, Large Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC), Extrapulmonary Neuroendocrine Carcinoma (EP-NEC), Small Cell Lung Cancer (SCLC)
- Trial name
- NCT07278479
- Testing
- [212Pb]Pb-MP0712, [203Pb]Pb-MP0712
- Where
- 8 sites in United States
- Volunteers
- 138 people
- Sponsor
- Molecular Partners AG
Gastroenteropancreatic Neuroendocrine Tumors
177Lutetium-octreotate Treatment Prediction Using Multimodality Imaging in Refractory NETs
The purpose of this study is to determine if 68Gallium-octreotate and 18Fluorodesoxyglucose uptake, apparent diffusion coefficient and post 177Lu-octreotate SPECT/CT dosimetry are reliable predictors for lesion-by-lesion…
- Trial name
- LUMEN (NCT01842165)
- Testing
- Intravenous injection of 177Lu-octreotate
- Where
- Belgium
- Volunteers
- 37 people
- Sponsor
- Jules Bordet Institute
Gastroenteropancreatic Neuroendocrine Tumors
Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors
There is limited evidence regarding the benefit of adding somatostatin analogs to molecular targeted agents for well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs) with poor prognostic factors.
- Trial name
- NCT07165886
- Testing
- Sirolimus for injection (albumin bound), Octreotide long-acting injection, Everolimus
- Where
- China
- Volunteers
- 298 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Small Cell Lung Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of [225Ac]Ac-ETN029 and the safety and imaging properties of [111In]In-ETN029 in patients aged ≥ 18 years with locally advanced…
- Conditions
- Small Cell Lung Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung, Neuroendocrine Prostate Cancer, Gastroenteropancreatic Neuroendocrine Carcinoma
- Trial name
- NCT07006727
- Testing
- 225Ac-ETN029, 111In-ETN029
- Where
- 8 sites in United States, Canada and 2 more
- Volunteers
- 116 people
- Sponsor
- Novartis Pharmaceuticals
Neuroendocrine Tumor, Gastroenteropancreatic
Surgical Intervention and the NETest
The purpose of this study is to evaluate the effect of different surgical resections (R0, R1, R2) on circulating NET transcripts (PCR score or NETest). A drop in circulating NET levels will be correlated with surgical excision.
- Trial name
- NETest_Sx (NCT03012789)
- Testing
- Surgery
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Wren Laboratories LLC
Carcinoma, Neuroendocrine
KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors
Evaluate the efficacy of Selinexor in patients with poorly differentiated lung and gastrointestinal and pancreatic neuroendocrine tumors.
- Trial name
- NCT02250885
- Testing
- Selinexor
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Gabrail Cancer Center Research
Advanced Solid Tumors
Evaluating the Safety, Tolerability, and Preliminary Anti-tumor Activity of MB0151 in Adult Subjects With Advanced Solid Tumors Expressing Somatostatin Receptors
This is a multicenter, open-label, single-arm, dose-escalation and dose-expansion Phase I/II study to evaluate the safety, tolerability and preliminary anti-tumor activity of MB0151 in adult subjects (at least 18 years old) with…
- Trial name
- NCT06840821
- Testing
- MB0151 for injection
- Where
- China
- Volunteers
- 156 people
- Sponsor
- Mainline Biosciences (Shanghai) Co., Ltd
Neuroendocrine Tumors
Peptide Receptor Radionuclide Therapy in the Treatment of Advanced, Non-resectable and/or Symptomatic Tumors With SSTR Overexpression
This is a non-randomized phase II , open label, comparative study. Patients with advanced non-resectable and/or progressive gastro-entero-pancreatic Neuroendocrine Tumours - GEP-NET, (G1, G2 and G3), Broncho-pulmonary Carcinoids…
- Trial name
- POLNETS_PRRT (NCT04029428)
- Testing
- 90Y-DOTATATE, (177Lu-DOTAOTyr3)Octreotate, 90Y DOTATATE and 177Lu DOTATATE (mix each of 50%)
- Where
- Poland
- Volunteers
- 150 people
- Sponsor
- University of Warmia and Mazury
Neuroendocrine Tumors
Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE
The purpose of the study is to evaluate the efficacy, safety \& patient-reported outcomes of peptide receptor radionuclide therapy (PRRT) with 177Lu-Edotreotide as 1st or 2nd line of treatment compared to best standard of care in…
- Trial name
- COMPOSE (NCT04919226)
- Testing
- 177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT, CAPTEM (Capecitabine and Temozolomide), Amino-Acid Solution
- Where
- 42 sites in United States, Australia and 8 more
- Volunteers
- 259 people
- Sponsor
- ITM Solucin GmbH
Neuroendocrine Carcinoma
Study of Everolimus as Maintenance Therapy for Metastatic NEC With Pulmonary or Gastroenteropancreatic Origin
Cisplatin and Etoposide is the standard of care in NEC originating from the gastro-intestinal tract and lung, based on retrospective studies.
- Trial name
- NCT02687958
- Testing
- Everolimus
- Where
- 5 sites in Italy
- Volunteers
- 30 people
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
NET, Radionucleide Therapy
DCEUS to Assess Treatment Response to PRRT in GEP-NET
Neuroendocrine tumors (NETs) are a wide group of neoplasms arising from the diffuse neuroendocrine cell system that features significant molecular and biological heterogeneity.
- Conditions
- NET, Radionucleide Therapy, Contrast Enhanced Ultrasound
- Trial name
- DCEUS-PRRT (NCT07319416)
- Testing
- Vuebox
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Neuroendocrine Tumors
A Study to Evaluate the Value of Circulating Tumour DNA in Follow-up of Patients With an Advanced Gastroenteropancreatic or Lung Neuroendocrine Tumour Under Everolimus +- SSA Treatment (Liquid-NET 2.0)
Prospective, multicentric, single arm, POC study to evaluate the value of CtDNA in follow-up of patients treated with everolimus, with or without somatostatin analogues for advanced gastroenteropancreatic or lung neuroendocrine…
- Trial name
- NCT05268952
- Testing
- Liquid biopsies, Scans (CT, gallium-68 DOTATE/TOC/NOC PET-CT)
- Where
- 3 sites in Belgium, Cyprus
- Volunteers
- 100 people
- Sponsor
- University Hospital, Antwerp
Neuroendocrine Tumors
Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients
The purpose of the study is to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive…
- Trial name
- COMPETE (NCT03049189)
- Testing
- 177Lu-edotreotide PRRT, Everolimus, Amino-Acid Solution
- Where
- 52 sites in United States, Australia and 12 more
- Volunteers
- 324 people
- Sponsor
- ITM Solucin GmbH
Metastatic Digestive System Neuroendocrine Neoplasm, Metastatic Neuroendocrine Tumor
Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors
This phase I trial studies the side effects and best dose of triapine when given together with lutetium Lu 177 dotatate in treating patients with neuroendocrine tumors.
- Trial name
- NCT04234568
- Testing
- Biospecimen Collection, Computed Tomography, Lutetium Lu 177 Dotatate
- Where
- 11 sites in United States
- Volunteers
- 31 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Well Differentiated Neuroendocrine Neoplasm, Neuroendocrine Tumors
A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NET
A Phase II trial aiming to assess the safety and activity of the combination of cabozantinib plus lanreotide in gastroenteropancreatic (GEP) and thoracic neuroendocrine tumor (NET): The LOLA trial
- Trial name
- LOLA (NCT04427787)
- Testing
- Cabozantinib, Lanreotide
- Where
- Italy
- Volunteers
- 69 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano